Androstenedione: The Essential Steroid Precursor

Serving as a fundamental biochemical nexus in human endocrinology, androstenedione represents the primary intermediate through which the body synthesizes both dominant male and female sex steroids. Far from functioning merely as a passive biological substrate, this endogenous prohormone influences systemic homeostasis, secondary sexual differentiation, and neuroendocrine signaling across the lifespan. A nuanced examination of androstenedione provides profound clinical and physiological insights into adrenal pathology, gonadal function, metabolic health, and pharmacological manipulation in athletic contexts.

Androstenedione

1. Concise Definition

Androstenedione (chemically designated as androst-4-ene-3,17-dione) is an endogenous 19-carbon steroid hormone that functions as an intermediate in the biosynthetic pathway producing testosterone and estrone. Synthesized predominantly within the adrenal cortices and gonads, it exhibits weak direct androgenic receptor affinity while exerting broad biological influence through its downstream metabolic conversions.

Biochemically, androstenedione occupies a decisive position at the crossroad of androgen and estrogen synthesis. It is synthesized directly from dehydroepiandrosterone (DHEA) by the action of 3β-hydroxysteroid dehydrogenase (3β-HSD), or alternatively from 17α-hydroxyprogesterone via the lyase activity of cytochrome P450 17A1 (CYP17A1). Once generated, it serves as the direct immediate precursor to testosterone via the catalytic reduction performed by 17β-hydroxysteroid dehydrogenase (17β-HSD), and to estrone through aromatic conversion by the enzyme cytochrome P450 19A1, widely known as aromatase.

Because of this bi-directional potential, androstenedione is critical for establishing normal endocrine equilibrium in both biological sexes. In biological females, it constitutes a substantial source of circulating androgens and forms the indispensable substrate for peripheral and ovarian estrogen generation, whereas in males, it serves as a secondary androgenic pool augmenting testicular production. Pathophysiological deviations in its circulating concentrations correlate strongly with metabolic dysfunctions, gonadal failures, and neoplastic developments.

2. Etymology & Linguistic Origin

The systematic nomenclature of androstenedione derives directly from classical chemical and morphological etymology rooted in Ancient Greek and modern biochemical conventions. The initial combining form andro- originates from the Ancient Greek an  r (ανηρ), genitive andros (ανδρος), denoting “man” or “masculine.” This morpheme historically identifies molecules exhibiting androgenic, masculinizing properties or structures structurally congruent with steroid precursors discovered in male reproductive biology.

The central constituent -sten- is an elided contraction derived from the fundamental steroid skeleton nomenclature, signifying the parent hydrocarbon androstane, combined with the chemical unsaturation infix -en- (from Greek -ene, denoting a carbon-carbon double bond, specifically at the C4 position in the steroid cyclopentanoperhydrophenanthrene ring system). The terminal suffix -dione reflects the presence of two separate ketone functional groups (=O), positioned systematically at carbon 3 on ring A and carbon 17 on ring D. The term gained widespread currency throughout the 1930s following its systematic synthesis and crystallization within German and Swiss organic chemistry laboratories.

3. Pronunciation & Grammatical Form

Pronunciation: Phonetically transcribed as /æn.droʊ.stti:nˈdaɪ.oʒn/ or /æn.drə.stɛnˈdaɪ.oʒn/. Colloquially, particularly within historical athletic and dietary supplement subcultures, the compound was frequently abbreviated as “andro” (/ˈæn.droʒ/).

Grammatical Form: Uncountable noun (mass noun). Syntactically, it behaves like other biochemical entities such as aldosterone or progesterone. Derived adjectival formations include androstenedione-dependent, androstenedione-mediated, and androstenedionic (rare). It does not take an operative plural form except when referring collectively to specific isotopic or stereochemical variants (“androstenediones”).

4. Detailed Conceptual Explanation

To fully grasp the scope and boundaries of androstenedione, one must analyze its location within the intricate cascade of human steroidogenesis. The generation of androstenedione begins universally with the mobilization of free intracellular cholesterol into the inner mitochondrial membrane, catalyzed by the steroidogenic acute regulatory (StAR) protein. Within the mitochondrion, the side-chain cleavage enzyme P450scc (CYP11A1) converts cholesterol into pregnenolone, representing the committed step of steroid hormone biosynthesis. From pregnenolone, steroidogenesis diverges into the Δ⁵ pathway (utilizing molecules retaining the C5-C6 double bond) and the Δ⁴ pathway (utilizing molecules with the C4-C5 double bond).

Androstenedione operates centrally at the convergence of both pathways. Within the adrenal cortex—specifically localized within the zona reticularis—and the ovarian theca interna cells, the Δ⁵ intermediate DHEA undergoes enzymatic modification by the microsomal enzyme 3β-hydroxysteroid dehydrogenase / Δ⁵-Δ⁴ isomerase (3β-HSD2), which concurrently oxidizes the 3β-hydroxyl group to a ketone and shifts the double bond from ring B to ring A. Simultaneously, through the Δ⁴ branch, 17α-hydroxyprogesterone can be converted into androstenedione via the 17,20-lyase activity of the bifunctional enzyme CYP17A1. In human physiology, the Δ⁵ pathway predominates significantly for the generation of C19 androgens, meaning that the overwhelming majority of androstenedione derives directly from DHEA.

Once synthesized, the bio-distribution of androstenedione exhibits marked sex-specific dynamics. In adult males, approximately 50% to 60% of circulating androstenedione originates from the adrenal glands, with the remainder generated by testicular Leydig cells. In adult, premenopausal females, its production rate is equally divided, with roughly half emanating from the adrenal zona reticularis and half arising from the ovarian theca interna cells under the trophic control of luteinizing hormone (LH). Circulating concentrations of androstenedione fluctuate across the female menstrual cycle, reaching an apex around the mid-cycle ovulatory peak, closely mirroring estradiol surges.

Functionally, androstenedione acts as a relatively weak agonist at the classical intracellular androgen receptor (AR), displaying an affinity that is estimated to be merely 2% to 10% of that observed for testosterone, and less than 1% of the potent affinity displayed by 5α-dihydrotestosterone (DHT). Consequently, its physiological importance is not predominantly defined by direct transcriptional activation via the AR. Rather, its physiological and clinical significance lies in its potential as a prohormone. Circulating androstenedione acts as an endocrine reserve that diffuses passively into peripheral target tissues—such as adipose tissue, dermal fibroblasts, skeletal muscle, and the central nervous system—where local tissue-specific enzymes dictate its bioactivation into potent estrogens or robust androgens.

5. Historical Development

The biochemical identification and isolation of androstenedione trace back to the golden era of steroid chemistry during the early-to-mid twentieth century. In 1935, Swiss chemist Leopold Ružička and his collaborators synthesized and structurally characterized the hormone concurrently with Adolf Butenandt in Germany, both of whom later received the Nobel Prize in Chemistry in 1939 for their independent work synthesizing sex hormones. Initially isolated from testicular extracts and mammalian urine, androstenedione provided crucial clarity on how low-potency adrenal secretions converted into more biologically active masculine factors.

Throughout the 1950s and 1960s, academic endocrinology integrated androstenedione into the broader conceptualization of adrenal steroidogenesis, propelled by the pioneering work of Seymour Lieberman and Gregory Pincus. The discovery that androstenedione acts as the direct metabolic precursor of estrone illuminated the etiology of postmenopausal estrogen dynamics and peripheral aromatization in non-gonadal tissues, establishing modern therapeutic frameworks for endocrine-responsive breast cancer.

In the late 20th century, the cultural and pharmacological status of androstenedione fundamentally shifted from academic biochemistry to athletic controversies. During the 1970s and 1980s, the state-sponsored sports doping apparatus of the German Democratic Republic (East Germany) developed nasal sprays and oral administrations of androstenedione as non-detectable ergogenic aids designed to rapidly elevate circulating testosterone levels in elite athletes without triggering standard steroid detection thresholds.

This covert usage transitioned into widespread public consumption in the United States following the passage of the Dietary Supplement Health and Education Act (DSHEA) of 1994, which legally classified androstenedione as a non-prescription dietary supplement. The compound gained massive media attention in 1998 when Major League Baseball player Mark McGwire acknowledged utilizing over-the-counter “andro” during his historic home-run chase. Subsequent scientific investigations firmly debunked its proposed ergogenic efficacy while delineating substantial health risks, leading the United States Food and Drug Administration (FDA) to issue compliance warnings, followed by the formal classification of androstenedione as a controlled anabolic steroid under the Anabolic Steroid Control Act of 2004.

6. Theoretical Foundations

The biological and clinical significance of androstenedione is grounded primarily in two enduring endocrine models: the Two-Cell, Two-Gonadotropin Theory of ovarian follicular steroidogenesis, and the Adrenarche and Neuroendocrine Maturation Model.

The Two-Cell, Two-Gonadotropin Theory, validated empirically across several decades of reproductive endocrinology, explains how ovarian follicles produce mature estrogens. Under this framework, two distinct cell types inside the developing follicle coordinate their actions under the influence of two pituitary gonadotropins:

• Theca Interna Cells: Express high concentrations of luteinizing hormone (LH) receptors. Binding of LH stimulates intracellular cyclic adenosine monophosphate (cAMP) cascades, upregulating CYP11A1, 3β-HSD, and CYP17A1. These cells efficiently synthesize C19 androgens, primarily androstenedione, but inherently lack the aromatase enzyme (CYP19A1).
• Granulosa Cells: Express follicle-stimulating hormone (FSH) receptors and lack significant 17,20-lyase activity, making them incapable of synthesizing androstenedione de novo from progesterone. However, FSH stimulation robustly induces CYP19A1 (aromatase) transcription.

Consequently, androstenedione synthesized within theca cells traverses the basal lamina into adjacent granulosa cells, where aromatase readily metabolizes it into estrone, which is then converted by 17β-HSD1 into 17β-estradiol. This metabolic cooperation illustrates androstenedione’s vital intermediary role in female fecundity and menstrual regulation.

The second foundational model concerns human developmental biology, specifically the phenomenon of adrenarche. Unique to higher primates, adrenarche represents the developmental maturation of the adrenal zona reticularis occurring around ages 6 to 8. This phase is characterized by a selective surge in the activity of CYP17A1 (favoring 17,20-lyase activity via cytochrome b5 electron transport coupling) without a concomitant increase in aldosterone or cortisol production. This developmental shift produces marked escalations in circulating DHEA, DHEA-sulfate, and androstenedione. Within this theoretical framework, androstenedione serves as a critical developmental trigger that mediates pubarche (the development of pubic and axillary hair), subtle accelerations in skeletal maturation, and changes in cutaneous sebum production independently of gonadal activation.

7. Key Components, Types & Dimensions

The structural, physiological, and clinical landscape of androstenedione encompasses several discrete dimensions, organized by origin, metabolic trajectories, and biochemical characteristics:

• Primary Anatomical Sources:
  • Adrenal Component: Produced in the zona reticularis under the regulatory oversight of adrenocorticotropic hormone (ACTH). Adrenal output exhibits a marked diurnal rhythm congruent with cortisol.
  • Gonadal Component: Synthesized by the ovarian theca interna (regulated by LH) and the testicular Leydig cells. Gonadal production fluctuates cyclically across the female reproductive lifespan and remains relatively steady in adult males.
• Divergent Metabolic Fates:
  • Androgenic Pathway: Mediated by the enzyme 17β-hydroxysteroid dehydrogenase type 3 (in testes) or type 5 (in peripheral tissues), reducing the 17-ketone into a 17β-hydroxyl group to yield testosterone.
  • Estrogenic Pathway: Mediated by the cytochrome P450 enzyme aromatase (CYP19A1), which transforms the A-ring into an aromatic phenol ring, converting androstenedione directly into estrone.
  • 5α-Reduction Pathway: Conversion by 5α-reductase into androstanedione (5α-androstane-3,17-dione), which serves as an alternative, non-aromatizable route toward potent dihydrotestosterone (DHT) synthesis through the “backdoor” steroidogenic pathway.
• Circulatory Dynamics:
  • Protein Binding: Unlike testosterone, which binds with strong affinity to Sex Hormone-Binding Globulin (SHBG), androstenedione binds primarily to serum albumin with low affinity and displays negligible binding to SHBG. As a consequence, a notably higher proportion (approximately 7% to 12%) of total circulating androstenedione exists in the free, non-protein-bound state.

8. Examples & Illustrative Cases

To conceptualize the systemic actions of androstenedione, consider three distinct clinical and pharmacological scenarios:

Case 1: Polycystic Ovary Syndrome (PCOS)
A 24-year-old female presents with severe oligomenorrhea, cystic acne, and progressive hirsutism along the chin and lower abdomen. Endocrine testing indicates elevated serum luteinizing hormone relative to follicle-stimulating hormone (an LH:FSH ratio > 2:1), along with markedly elevated total testosterone and an androstenedione concentration of 4.8 ng/mL (reference: 0.6–2.7 ng/mL). In this context, enhanced LH pulsatility drives excessive theoretical expression of CYP17A1 in hypertrophied theca interna cells. The theca cells produce massive quantities of androstenedione that overwhelm granulosa cell aromatization capacity. The unaromatized androstenedione spills into systemic circulation and converts peripherally to testosterone and DHT, leading to cutaneous hirsutism, sebaceous hypersecretion, follicular arrest, and chronic anovulation.

Case 2: Congenital Adrenal Hyperplasia (CAH) via 21-Hydroxylase Deficiency
A newborn infant presents with ambiguous genitalia, and genetic testing confirms a 46,XX karyotype. Biochemical assays reveal deficient levels of serum cortisol and aldosterone paired with an extreme accumulation of 17α-hydroxyprogesterone (17-OHP). Because the 21-hydroxylase (CYP21A2) block impedes the conversion of 17-OHP to 11-deoxycortisol, elevated hypothalamic CRH and pituitary ACTH continuously stimulate the adrenal cortex. The steroid intermediates are shunted into the intact androgen pathway, resulting in supranormal adrenal production of androstenedione. This surplus androstenedione is subsequently metabolized peripherally into active testosterone in utero, causing virilization of the female external genitalia without altering internal Mullerian structures.

Case 3: Pharmacological Misuse (Athletic Prohormone Doping)
A 28-year-old male bodybuilder ingests 300 mg of oral androstenedione daily, believing it will safely elevate muscle hypertrophy via amplified systemic testosterone. Within six weeks, serum analyses demonstrate only minor, transient elevations in free testosterone, but reveal a four-fold increase in circulating estrone and estradiol. Due to hepatic first-pass metabolism, oral androstenedione encounters abundant liver aromatase and hepatic 17β-HSD enzymes, preferentially shunting the exogenous substrate into estrogenic pathways. Clinically, the individual develops bilateral tender gynecomastia, fluid retention, down-regulated endogenous gonadotropin secretion (reduced LH/FSH), and impaired spermatogenesis, demonstrating how exogenous precursor loading can induce diametrically opposed physiological consequences.

9. Measurement & Assessment

Accurate quantification of androstenedione is essential for investigating hyperandrogenic states, adrenal tumors, and enzyme deficiencies. However, analytical methodologies differ markedly in clinical sensitivity and diagnostic specificity.

Historically, quantification relied upon direct radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). While cost-effective and straightforward, immunoassays often suffer from significant cross-reactivity with structurally homologous steroid analogs, including DHEA, testosterone, and conjugated steroid metabolites. Immunoassays often yield falsely elevated results, especially at low baseline concentrations observed in pediatric populations, postmenopausal women, and hypogonadal males.

Consequently, the current gold standard across clinical chemistry is liquid chromatography-tandem mass spectrometry (LC-MS/MS), frequently combined with high-performance extraction techniques. LC-MS/MS offers superior chromatographic resolution, distinguishing androstenedione cleanly from isobaric steroids such as 17α-hydroxyprogesterone and epitestosterone. Diagnostic workups typically require serum or plasma samples collected in the early morning (between 07:00 and 09:00), which accounts for the hormone’s marked diurnal rhythm coordinated by episodic ACTH release. Typical physiological reference intervals for adult males approximate 0.6 to 2.7 ng/mL (2.1 to 9.4 nmol/L), whereas values for adult females typically fall between 0.5 and 2.5 ng/mL (1.7 to 8.7 nmol/L), fluctuating slightly based on menstrual phase.

10. Applications & Practical Significance

The monitoring and clinical application of androstenedione metrics provide critical utility across numerous diagnostic and therapeutic domains:

• Differential Diagnosis of Hyperandrogenism: Clinicians rely on simultaneous measurements of androstenedione, total testosterone, and DHEA-sulfate to pinpoint the exact etiology of virilization. While isolated elevations of DHEA-sulfate strongly indicate adrenal pathology (such as adrenal adenoma, carcinoma, or non-classical CAH), elevated androstenedione paired with high testosterone points directly to ovarian pathology, including PCOS or rare arrhenoblastomas.
• Oncology & Therapeutic Monitoring: In hormone receptor-positive postmenopausal breast cancer, peripheral androstenedione is converted by local adipose tissue aromatase into estrogens that drive tumor growth. Monitoring and suppressing androstenedione-to-estrogen pathways underpins the clinical efficacy of third-generation aromatase inhibitors (such as letrozole, anastrozole, and exemestane).
• Anti-Doping Oversight: The World Anti-Doping Agency (WADA) classifies androstenedione as a prohibited non-specified anabolic androgenic steroid under Section S1.1 of the Prohibited List. Anti-doping laboratories detect exogenous androstenedione administration by monitoring urinary steroid profiles via Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS). This approach detects shifts in carbon-13/carbon-12 (δ¹³C) isotopic ratios, distinguishing synthetic steroid derivatives derived from plant sterols from endogenous biological molecules.

11. Research & Empirical Evidence

The pharmacokinetic and ergogenic properties of androstenedione were rigorously scrutinized following its explosive popularity as an over-the-counter athletic supplement in the late 1990s. The commercial rationale asserted that oral androstenedione would pass efficiently into the bloodstream, undergo enzymatic conversion via endogenous 17β-HSD3, raise circulating testosterone, and facilitate skeletal muscle protein synthesis.

A landmark randomized controlled trial conducted by King et al. (1999) directly tested this hypothesis. Young, resistance-trained male subjects were administered either a placebo or 300 mg daily of oral androstenedione while completing an eight-week intensive resistance training regimen. The researchers observed that oral androstenedione did not significantly elevate serum free or total testosterone concentrations compared to controls, nor did it enhance muscular strength or facilitate lean body mass accretion. Instead, the experimental cohort exhibited statistically significant elevations in circulating estrone and estradiol, alongside marked reductions in high-density lipoprotein cholesterol (HDL-C), increasing cardiovascular risk profiles.

Subsequent mechanistic trials led by Leder et al. (2000) systematically administered escalating doses of androstenedione (100 mg and 300 mg daily) to healthy young men. While the high-dose 300 mg regimen generated modest, brief peaks in serum testosterone, these surges were accompanied by steep, sustained escalations in estrogenic metabolites. These empirical findings confirmed that hepatic first-pass metabolism effectively diverts oral androstenedione through CYP19A1-mediated aromatization and 5β-reductase degradation rather than productive muscle-directed testosterone synthesis. These observations dismantled the theoretical framework behind marketing androstenedione as a safe, effective alternative to anabolic steroids.

12. Cultural & Cross-Cultural Considerations

The cultural positioning and legal classification of androstenedione reveal contrasting philosophies of public health, dietary supplement regulation, and pharmacology across the globe. In the United States, the distinct regulatory framework introduced by DSHEA created an environment in which androstenedione was commercialized, widely marketed, and openly purchased in conventional nutrition stores for nearly a decade without mandatory pre-market safety testing.

This accessibility shaped broader cultural perceptions of performance-enhancing drugs during the late 1990s and early 2000s, leading the general public to view steroid precursors as harmless nutritional supplements rather than active hormonal compounds. This permissive environment contrasted sharply with regulations across Western Europe, Australia, and Canada, where androstenedione was consistently treated as an unapproved prescription pharmaceutical or a controlled, prohibited substance subject to rigorous manufacturing and distribution bans.

The cultural reckoning stemming from professional sports scandals gradually prompted US regulatory realignment. The eventual categorization of androstenedione under Schedule III of the Controlled Substances Act in 2004 established international alignment, reinforcing the clinical consensus that hormone precursors capable of systemic biological modification necessitate the same rigorous oversight as synthetic anabolic steroids.

13. Criticisms, Debates & Limitations

Extensive clinical and pharmacological investigations have brought several critical debates surrounding androstenedione to light:

• The Myth of Oral Bioavailability and Ergogenic Efficacy: The central pharmacological critique of androstenedione centers on its rapid hepatic clearance and low systemic bioavailability when taken orally. First-pass metabolism degrades oral androstenedione extensively into inactive hepatic conjugates (such as androsterone and etiocholanolone) or rapidly aromatizes it into estrogens. Athletes consuming oral doses frequently subjected their hepatic and cardiovascular systems to significant stress without acquiring measurable anabolic advantages.
• Unbalanced Estrogenic Shunting: Because androstenedione is a direct substrate for the aromatase enzyme, systemic elevations frequently drive estrogen levels upward disproportionately relative to androgens. In men, this often precipitates gynecomastia, central adiposity, fluid retention, and secondary suppression of the hypothalamic-pituitary-gonadal (HPG) axis via estrogen-mediated negative feedback on hypothalamic GnRH release.
• Cardiovascular and Atherogenic Derangements: Clinical trials consistently highlight that sustained exogenous androstenedione administration significantly lowers protective circulating HDL cholesterol, without improving vascular function. This altered lipid profile, combined with potential secondary hematocrit elevations, significantly escalates long-term atherogenic and thrombotic risks.
• Diagnostic Ambiguity in Clinical Endocrinology: When using androstenedione measurements to pinpoint endocrine pathology, clinicians face diagnostic overlap. Modest elevations can emerge from benign functional adrenal hyperfunction, chronic psychological or physiological stress, metabolic syndrome, or mild non-classical congenital adrenal hyperplasia, making isolated values insufficient for definitive clinical conclusions without broader multisteroid panel profiling.

14. Related Terms & Distinctions

Understanding androstenedione requires delineating its distinct biochemical profile relative to several closely related androgens and steroid precursors:

• Dehydroepiandrosterone (DHEA):
  Distinction: DHEA is a Δ⁵-steroid retaining a 3β-hydroxyl group and a double bond between C5 and C6, whereas androstenedione is a Δ⁴-steroid with a C3 ketone and a C4-C5 double bond. DHEA is synthesized primarily in the adrenal glands and circulates at far higher concentrations, mostly as DHEA-sulfate (DHEA-S). It acts upstream of androstenedione in the steroidogenic cascade.
• Testosterone:
  Distinction: Testosterone possesses a hydroxyl (-OH) group at the C17 position rather than a ketone (=O). It exhibits high-affinity binding to the androgen receptor, yielding robust direct anabolic and androgenic actions, whereas androstenedione must primarily undergo 17β-reduction into testosterone to exert significant androgenic potency.
• Estrone (E1):
  Distinction: Estrone is the primary downstream estrogenic metabolite of androstenedione, derived directly via the enzyme aromatase (CYP19A1). Unlike the non-aromatic, four-ring steroid structure of androstenedione, estrone features a fully aromatic, phenolic A-ring.
• Androsterone:
  Distinction: Androsterone is an inactive or weakly active down-stream breakdown product and metabolite of androstenedione and testosterone, excreted via urine following hepatic 5α-reduction and 3α-hydroxysteroid dehydrogenase reduction.
• Dihydrotestosterone (DHT):
  Distinction: DHT is a fully 5α-reduced terminal androgen that cannot be aromatized into estrogens. It binds the androgen receptor with roughly two to three times the affinity of testosterone and up to fifty times that of androstenedione.

15. Summary / Key Takeaways

Androstenedione occupies a pivotal position in steroid biochemistry, functioning as the shared precursor for both primary androgens and estrogens. Synthesized symmetrically between the adrenal cortex and the gonads, its systemic expression reflects broader neuroendocrine coordination and tissue-specific enzymatic balance. While historical commercial marketing falsely promoted androstenedione as a harmless, highly effective oral muscle-building compound, clinical and empirical research has conclusively revealed that exogenous supplementation fails to stimulate muscle hypertrophy, instead shunting into circulating estrogens and provoking substantial cardiovascular and endocrine risks. In contemporary medical practice, androstenedione serves primarily as an essential diagnostic biomarker, aiding clinicians in unraveling the etiology of complex hyperandrogenic disorders, monitoring congenital enzymatic disruptions, and understanding hormone-responsive pathologies.

Ultimately, androstenedione illustrates the nuanced interconnectedness and tight regulatory controls of human endocrinology. Its dual metabolic fates highlight that hormonal activity relies not merely on circulating baseline concentrations, but on the delicate, localized enzymatic machinery that converts systemic precursors into functional downstream hormones.

References

• King, D. S., Sharp, R. L., Vukovich, M. D., De Luca, G. A., Caine, N. L., Angelopoulos, T. J., & Lee, P. C. (1999). Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: A randomized controlled trial. JAMA, 281(21), 2020–2028. https://doi.org/10.1001/jama.281.21.2020
• Leder, B. Z., Longcope, C., Catlin, D. H., Ahrens, B., Schoenfeld, D. A., & Finkelstein, J. S. (2000). Oral androstenedione administration and serum testosterone concentrations in young men. JAMA, 283(6), 779–782. https://doi.org/10.1001/jama.283.6.779
• Miller, W. L., & Auchus, R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews, 32(1), 81–151. https://doi.org/10.1210/er.2010-0013
• Ružička, L., & Wettstein, A. (1935). Künstliche Herstellung des Testikelhormons Androsten-3-on-17-ol (Testosteron). Helvetica Chimica Acta, 18(1), 1264–1275. https://doi.org/10.1002/hlca.193501801176
• World Anti-Doping Agency. (2024). The World Anti-Doping Code International Standard Prohibited List. World Anti-Doping Agency. https://www.wada-ama.org/